Skip to main navigation Skip to search Skip to main content

Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay.

  • Matthew J. Murray
  • , Megan McIntosh
  • , Claire Atkinson
  • , Tabitha Mahungu
  • , Edward Wright
  • , Wendy Chatterton
  • , Michael Gandy
  • , Matthew B. Reeves
  • University College London
  • Institute of Immunity and Transplantation
  • Royal Free London NHS Foundation Trust
  • University of Sussex
  • Health Services Laboratories LLP

Research output: Contribution to journal › Article › peer-review

26 Citations (Scopus)
2 Downloads (Pure)

Abstract

Objectives: To assess whether a commercially available CE-IVD, ELISA-based surrogate neutralisation assay (cPass, Genscript) provides a genuine measure of SARS-CoV-2 neutralisation by human sera, and further to establish whether measuring responses against the RBD of S was a diagnostically useful proxy for responses against the whole S protein. Methods: Serum samples from 30 patients were assayed for anti-NP responses, for ‘neutralisation’ by the surrogate neutralisation assay and for neutralisation by SARS-CoV-2 S pseudotyped virus assays utilising two target cell lines. Correlation between assays was measured using linear regression. Results: The responses observed within the surrogate neutralisation assay demonstrated an extremely strong, highly significant positive correlation with those observed in both pseudotyped virus assays. Conclusions: The tested ELISA-based surrogate assay provides an immunologically useful measure of functional immune responses in a much quicker and highly automatable fashion. It also reinforces that detection of anti-RBD neutralising antibodies alone is a powerful measure of the capacity to neutralise viral infection.

Original languageEnglish
Pages (from-to)170-177
Number of pages8
JournalJournal of Infection
Volume82
Issue number5
DOIs
Publication statusPublished - 20 Mar 2021
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay.'. Together they form a unique fingerprint.

Cite this